Metabolic disorder-associated target gene irna compositions and methods of use thereof
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsAimee M. Deaton, Jeffrey Zuber
Life of this patent
Estimating the term…
Abstract
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting a metabolic disorder-associated target gene, e.g., inhibin subunit beta E (INHBE), activin A receptor type 1C (ACVR1C), perilipin-1 (PLIN1), phosphodiesterase 3B (PDE3B), or inhibin subunit beta C (INHBC) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a metabolic disorder-associated target gene and to methods of preventing and treating a metabolic disorder, e.g., metabolic syndrome.
Claims39
A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of a metabolic disorder-associated target gene selected from the group consisting of inhibin subunit beta E (INHBE), activin A receptor type 1C (ACVR1C), perilipin-1 (PLIN1), phosphodiesterase 3B (PDE3B), and inhibin subunit beta C (INHBC) in a cell,
- wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region,
- a) wherein the metabolic disorder-associated target gene is INHBE and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense strand nucleotide sequences selected from the group consisting of
- SEQ ID NO:
- 6245
- 5′-AAAGACGGCAGAAUGGAAAGAGG-3′ of;
- SEQ ID NO:
- 64
- 5′-AAGAAAGUAUAAAUGCUUGUCUC-3′ of;
- SEQ ID NO:
- 63
- 5′-ACAGACAAGAAAGUGCCCAUUUG-3′ of;
- SEQ ID NO:
- 58
- 5′-AGUUAUTCUGGGACGACUGGUCU-3′ of;
- and
- SEQ ID NO:
- 6403
- 5′-AAAGCCAGAGUCUCAGACAAGAA-3′ of.
- and
- wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a nucleotide modification
- b) wherein the metabolic disorder-associated target gene is INHBE and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from the complement of any one of the nucleotide sequence of nucleotides 400-422, 1430-1452, 1863-1885, 410-432, 518-540, 519-541, 640-662, or 1864-1886 of SEQ ID NO:
- 1;
- c) wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of any one of SEQ ID NOs:
- 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, or 55, and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the corresponding portion of the nucleotide sequence of any one of SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, or 56;
- d) wherein the antisense strand comprises a region of complementarity to an mRNA encoding the target gene, and wherein the region of complementarity comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense nucleotide sequences in any one of Tables 2-17, 19 and 20.
-22. (canceled)
(canceled)
-30. (canceled)
(canceled)
-38. (canceled)
-43. (canceled)
(canceled)
-69. (canceled)
(canceled)
(canceled)
-121. (canceled)
-128. (canceled)
-144. (canceled)
-169. (canceled)
-173. (canceled)
Dependencies are inferred from the claim text.